Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 13/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5399629 | 0.90 | PDE1A (0.38) | SLC16A1KDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL6677611 | 0.87 | PDE1A (0.36) | SLC16A1TSHR | |
| SCHEMBL5419638 | 0.85 | PDE1A (0.39) | SLC16A1ALDH1A1TSHRGRIN1GRIN2B | |
| SCHEMBL5403011 | 0.83 | ADORA2A (0.40) | SLC16A1 | |
| SCHEMBL5395371 | 0.82 | SLC16A1 (0.52) | SLC16A1ALDH1A1TSHRNPSR1 | |
| SCHEMBL5404652 | 0.82 | RIPK3 (0.41) | — | |
| SCHEMBL5400574 | 0.82 | ADORA2B (0.48) | KDM4EALDH1A1HPGDTSHRNPSR1 | |
| SCHEMBL5393955 | 0.80 | NR1H2 (0.45) | SLC16A1KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL5419589 | 0.80 | PDE1A (0.52) | HPGD | |
| SCHEMBL5395309 | 0.80 | PDE1A (0.37) | SLC16A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | SLC16A1 4140/4885KDM4E 3332/4885ALDH1A1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.